Schapira, M., Calabrese, M. F., Bullock, A. N. & Crews, C. M. Targeted protein degradation: expanding the toolbox. Nat. Rev. Drug Discov. 18, 949–963 (2019).
Chamberlain, P. P. & Hamann, L. G. Development of targeted protein degradation therapeutics. Nat. Chem. Biol. 15, 937–944 (2019).
Zhao, L., Zhao, J., Zhong, K., Tong, A. & Jia, D. Targeted protein degradation: mechanisms, strategies and application. Signal Transduct. Target. Ther. 7, 113 (2022).
Hu, Z. & Crews, C. M. Recent developments in PROTAC-mediated protein degradation: from bench to clinic. ChemBioChem 23, e202100270 (2022).
Takahashi, D. et al. AUTACs: cargo-specific degraders using selective autophagy. Mol. Cell 76, 797–810.e10 (2019).
Ji, C. H. et al. The AUTOTAC chemical biology platform for targeted protein degradation via the autophagy–lysosome system. Nat. Commun. 13, 904 (2022).
Garber, K. The PROTAC gold rush. Nat. Biotechnol. 40, 12–16 (2022).
Banik, S. M. et al. Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature 584, 291–297 (2020).
Marei, H. et al. Antibody targeting of E3 ubiquitin ligases for receptor degradation. Nature 610, 182–189 (2022).
Zhang, P. et al. Cancer nanomedicine toward clinical translation: obstacles, opportunities, and future prospects. Med 4, 147–167 (2023).
Sousa de Almeida, M. et al. Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine. Chem. Soc. Rev. 50, 5397–5434 (2021).
Donahue, N. D., Acar, H. & Wilhelm, S. Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine. Adv. Drug Deliv. Rev. 143, 68–96 (2019).
Gautam, L. et al. Multicompartment systems: a putative carrier for combined drug delivery and targeting. Drug Discov. Today 27, 1184–1195 (2022).
Tsuchikama, K. & An, Z. Antibody–drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell 9, 33–46 (2018).
Xu, M. J., Johnson, D. E. & Grandis, J. R. EGFR-targeted therapies in the post-genomic era. Cancer Metastasis Rev. 36, 463–473 (2017).
Kjær, I. et al. Cetuximab resistance in squamous carcinomas of the upper aerodigestive tract is driven by receptor tyrosine kinase plasticity: potential for mAb mixtures. Mol. Cancer Ther. 15, 1614–1626 (2016).
Jiang, X. et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol. Cancer 18, 10 (2019).
Oh, D.-Y. & Bang, Y.-J. HER2-targeted therapies—a role beyond breast cancer. Nat. Rev. Clin. Oncol. 17, 33–48 (2020).
Jackson, C. B., Farzan, M., Chen, B. & Choe, H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. 23, 3–20 (2022).
Chen, Y. et al. ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blocker. Signal Transduct. Target. Ther. 6, 315 (2021).
Devarakonda, C. K. V., Meredith, E., Ghosh, M. & Shapiro, L. H. Coronavirus receptors as immune modulators. J. Immunol. 206, 923–929 (2021).
Tenchov, R., Bird, R., Curtze, A. E. & Zhou, Q. Lipid nanoparticles—from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. ACS Nano 15, 16982–17015 (2021).
Iversen, T.-G., Skotland, T. & Sandvig, K. Endocytosis and intracellular transport of nanoparticles: present knowledge and need for future studies. Nano Today 6, 176–185 (2011).
Ahn, G. et al. LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation. Nat. Chem. Biol. 17, 937–946 (2021).
Wang, R. et al. Molecular basis of V-ATPase inhibition by bafilomycin A1. Nat. Commun. 12, 1782 (2021).
Zhao, Y. G., Codogno, P. & Zhang, H. Machinery, regulation and pathophysiological implications of autophagosome maturation. Nat. Rev. Mol. Cell Biol. 22, 733–750 (2021).
Collier, J. J. et al. Developmental consequences of defective ATG7-mediated autophagy in humans. N. Engl. J. Med. 384, 2406–2417 (2021).
Wang, W. & Hu, Z. Targeting peptide-based probes for molecular imaging and diagnosis. Adv. Mater. 31, 1804827 (2019).
Huang, L. et al. Novel peptide inhibitors of angiotensin-converting enzyme 2. J. Biol. Chem. 278, 15532–15540 (2003).
Gao, C. et al. Autophagy negatively regulates Wnt signalling by promoting dishevelled degradation. Nat. Cell Biol. 12, 781–790 (2010).
Islam, M. A. et al. Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA. Nat. Biomed. Eng. 2, 850–864 (2018).
Tomayko, M. M. & Reynolds, C. P. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother. Pharmacol. 24, 148–154 (1989).
